Neurocrine Biosciences (NBIX) Free Cash Flow Growth (5y) (2015 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.39% |
| Mar 31, 2026 | 10.55% |
| Dec 31, 2025 | 34.14% |
| Sep 30, 2025 | 65.20% |
| Jun 30, 2025 | -4.76% |
| Mar 31, 2025 | 9.61% |
| Dec 31, 2024 | 19.95% |
| Sep 30, 2024 | 9.71% |
| Jun 30, 2024 | -2.35% |
| Mar 31, 2024 | 24.77% |
| Dec 31, 2023 | 21.56% |
| Sep 30, 2023 | 29.30% |
| Jun 30, 2023 | 61.28% |
| Mar 31, 2023 | -27.11% |
| Dec 31, 2022 | 29.88% |
| Sep 30, 2022 | 59.42% |
| Jun 30, 2022 | 36.03% |
| Mar 31, 2022 | 9.38% |
| Dec 31, 2021 | 31.85% |
| Sep 30, 2021 | 30.36% |